Enrollment is complete for a Phase 3 clinical trial testing Tyvaso (treprostinil) inhalation solution for idiopathic pulmonary fibrosis…
Articles by Andrea Lobo
AGMB-447, an inhaled treatment for idiopathic pulmonary fibrosis (IPF) now being tested in a Phase 1 clinical trial,…
Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary…
LTI-03, an inhaled therapy for idiopathic pulmonary fibrosis (IPF) from Aileron Therapeutics, was able to reduce levels of…
Endeavor BioMedicines has raised $132.5 million toward the clinical development of its pipeline programs, including ENV-101, an investigational oral…
Enrollment has been completed for a Phase 2b trial that’s testing LYT-100 (deupirfenidone), PureTech Health’s experimental therapy for…
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to BMS-986278, Bristol Myers Squibb’s investigational therapy…
The U.S. Food and Drug Administration (FDA) has approved a new generic version of Esbriet (pirfenidone) for idiopathic…
People with Sjögren’s syndrome-associated interstitial lung disease (ILD) who develop pulmonary fibrosis (PF) have poorer survival than those without…
People with shorter telomeres, or chromosome “caps,” may be at a greater risk of developing idiopathic pulmonary fibrosis (IPF),…